Researcher at Lewis Katz School of Medicine at Temple University and Fox Chase Co-Authors Study That Explains Why PIM Inhibitors Fall Short in Clinical Trials
PHILADELPHIA (November 29, 2023) — A new study co-authored by a researcher from the Lewis Katz School of Medicine at Temple University and Fox Chase Cancer Center helps explain why drugs targeting a type of enzyme called PIM kinases, which are known to play an important role in several cancers, have largely failed in clinical trials. The findings also indicate that another approach may be significantly more effective.